Buspirone/testosterone (tentative brand name Lybridos) is a combination of buspirone, a 5-HT1A receptor partial agonist, α2-adrenergic receptor antagonist, and D2 autoreceptor antagonist,[1] and testosterone, an androgen or androgen receptor agonist, which is under development by the pharmaceutical company Emotional Brain for the treatment of female sexual dysfunction.[2][3] Both buspirone and testosterone have individually been found to be effective in the treatment of female sexual dysfunction in clinical studies, and so their combination could be anticipated to be even more effective.[4][5][6] As of January 2016, the combination is in phase II clinical trials, with a phase III trial being planned in the United States and Europe.[2]
| Combination of | |
|---|---|
| Buspirone | 5-HT1A receptor agonist |
| Testosterone | Androgen (AR agonist) |
| Clinical data | |
| Other names | Lybridos |
| Legal status | |
| Legal status | |
See also
editReferences
edit- ^ Loane C, Politis M (June 2012). "Buspirone: what is it all about?". Brain Research. 1461: 111–118. doi:10.1016/j.brainres.2012.04.032. PMID 22608068. S2CID 11734819.
- ^ a b "Buspirone/Testosterone - Emotional Brain". AdisInsight. Springer Nature Switzerland AG.
- ^ Meston CM, Stanton AM (2017). "Treatment of Female Sexual Interest/Arousal Disorder". In IsHak WW (ed.). The Textbook of Clinical Sexual Medicine. pp. 165–168. doi:10.1007/978-3-319-52539-6_11. ISBN 978-3-319-52538-9.
- ^ Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, et al. (January 2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clinic Proceedings. 92 (1): 114–128. doi:10.1016/j.mayocp.2016.09.018. PMID 27916394.
- ^ Nappi RE, Cucinella L (April 2015). "Advances in pharmacotherapy for treating female sexual dysfunction". Expert Opinion on Pharmacotherapy. 16 (6): 875–887. doi:10.1517/14656566.2015.1020791. PMID 25732267. S2CID 24678911.
- ^ Bolour SY, Braunstein GD (September 2005). "Pharmacologic treatment options for hypoactive sexual desire disorder". Women's Health. 1 (2): 263–277. doi:10.2217/17455057.1.2.263. PMID 19803843.
External links
edit | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |